- Home
- YDES vs HQL Comparison
YDES vs HQL Comparison
Compare YDES & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | YDES | HQL |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 543.0M | 544.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | YDES | HQL |
|---|---|---|
| Price | $5.20 | $17.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 22.7K | ★ 105.0K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.20 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $11.88 |
| 52 Week High | $25.00 | $18.10 |
Technical Indicators
Market Signals| Indicator | YDES | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 56.83 |
| Support Level | N/A | $16.40 |
| Resistance Level | $13.19 | $17.80 |
| Average True Range (ATR) | 0.56 | 0.32 |
| MACD | 0.03 | -0.03 |
| Stochastic Oscillator | 13.42 | 47.06 |
Price Performance
Historical ComparisonAbout YDES YD Bio Limited Ordinary Shares
YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.